Probiotic supplement MPRO3 to help colon cancer surgery patients
Official title: AI-Assisted Microbiome Analysis for Evaluating the Efficacy of MPRO3 and Gut Environmental Changes in Colon Cancer Surgery Patients: A 13-Week, Randomized, Double-Blind, Placebo-Controlled Trial (AI-MPRO3 Study)
Run by hy Co., LTD. · NCT07792980 · Data updated 2026-11-12
This trial tests whether MPRO3 probiotic capsules given before and after colon cancer surgery reduce infection and improve gut health compared with a placebo.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | hy Co., LTD. Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul, Seoul) |
| Status | Recruiting |
| Started | August 4, 2026 |
| Main results expected | April 12, 2028 |
| Study ends | April 12, 2028 |
| Registry record updated | August 28, 2026 |
| Trial ID | NCT07792980 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with colon adenocarcinoma scheduled for surgical resection who have not recently received chemotherapy or radiotherapy for colon cancer.
✕Probably not a fit
Patients with significant comorbidities, immune disorders, recent probiotic use, or liver/kidney dysfunction may not benefit or could be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with colon cancer undergoing surgery will be randomized to receive MPRO3 or placebo daily starting one week before surgery and continuing for 12 weeks after. The study will compare postoperative infections, other clinical outcomes, and gut microbiome changes between groups. The approach uses AI-assisted microbiome analysis to explore how MPRO3 may influence gut environments around surgery. The trial is interventional with two arms and 13 weeks of dosing, focusing on surgical recovery and microbial alterations.
Why it matters
Potential benefit: If successful, MPRO3 could lower infection risk and support better gut health after colon cancer surgery.
How similar studies have gone: Previous probiotic approaches in surgical patients have shown mixed results; this trial explores a targeted mixture with AI-driven microbiome analysis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A person who is diagnosed histologically or radiologically with adenocarcinoma of the colon and is scheduled to undergo surgery Exclusion Criteria: * A person who has received chemotherapy or radiotherapy for colon cancer before surgery * A person with fecal incontinence * A person who has been diagnosed with an acute or serious disease, such as liver, kidney, heart, or thyroid disease, or is taking related medication * A person with alcohol dependence or a history of drug abuse * A person with immune system disorders, infectious diseases, or gastrointestinal diseases, including inflammatory bowel disease * A person who is currently diagnosed with or receiving treatment for another type of cancer * A person with renal dysfunction, defined as serum creatinine at least 1.5 times the upper limit of normal, or liver dysfunction, defined as AST and/or ALT at least 2.5 times the upper limit of normal * A person who has continuously used probiotics within the previous week * A person who is pregnant or lactating * A person who has hypersensitivity to the investigational product or any of its ingredients, or an allergy to a specific ingredient * A person who has participated in another human study or drug clinical trial within one month before the start of this study, except for a study involving only non-invasive surveys * A person who is unable to read letters or whose ability is limited * A person deemed inappropriate by the investigator to participate in this study for other reasons
Where it's running
-
Seoul ST. Mary's Hospital
Seoul, Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Nayeon Song
- Email: mind1088@naver.com
- Phone: +82-10-4365-1088
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut and tumor bacteria patterns in metastatic versus non-metastatic colorectal cancer
This project will test whether bacteria in the gut and tumor differ between people whose colorectal cancer has spread and those whose cancer has not to see if bacterial signatures can help predict spread.
-
Minimally invasive surgery for early-stage colon cancer
This study is testing a new, less invasive surgery for early-stage colon cancer to see if it can lower the chances of cancer coming back compared to the standard surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.